This study is for men and women who have had surgery to remove bladder cancer which is in the deep muscle of the bladder wall. The purpose of this study is to compare any good and bad effects of using a drug called MK-3475 (pembrolizumab) after the removal of your muscle invasive bladder cancer.
This is a study that will test how an experimental drug (enfortumab vedotin) combined with a kind of anticancer drug called an immune checkpoint inhibitor (CPI) affects patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra that has spread to nearby tissues or to other areas of the body.
The overall goal of this study is to see if adding radiation to a combination of chemotherapy agents can help to reduce the size of tumors in patients with metastatic clear-cell renal cell carcinoma (ccRCC) who have previously received nivolumab and progressed. The kind of radiation used is called hypo-fractionated stereotactic radiation (STR). The chemotherapy agents that will be administered will be a combination of ipilimumab and nivolumab.
This study will be conducted at MUSC and the VA on adult patients with newly diagnosed metastatic prostate cancer. The purpose of this study is to see if giving several cycles of docetaxel before androgen deprivation therapy (degarelix) improves outcomes, including survival rates, among men with metastatic prostate cancer. Patients will undergo screening assessments to see if they are eligible. Once on study, subjects will receive 6 cycles of docetaxel (cycle = 21 days). During cycle 4, subjects will begin taking degarelix every 28 days for up to 7 months.
This is a multi-institutional, randomized, placebo controlled, double-blinded phase II trial of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer who have achieved at least stable disease on first-line chemotherapy.